| Bioactivity | Crefmirlimab (89Zr-Df-IAB22M2C) is an anti-human CD8 probe targeting CD8 antigen, which can be used in the diagnosis of various cancers[1]. |
| Name | Crefmirlimab |
| CAS | 2611099-93-3 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Martin Hutchings, et al. CD8 Presence and Dynamics in Glofitamab-Treated Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Using the CD8-Specific PET Tracer 89Zr-Crefmirlimab Berdoxam. Blood (2022) 140 (Supplement 1): 10733-10735. |